# citi



## **Books Close/Open Notice**

May 19, 2023

| Company Name:       | Joincare Pharmaceutical Group Industry Co., Ltd. |
|---------------------|--|
| Ticker Symbol:      | JCARE SW   |
| CUSIP Number:       | 47973H205  |
| US ISIN:            | US47973H2058                                     |
| Country:            | China  |
| Listing Exchange:   | SIX  |
| Sponsorship Level:  | Sponsored GDR - Reg S Program                    |
| Ratio (ORD:DR):     | 10:1   |
| Books Closed Date:  | Close of business May 23, 2023                   |
| Books Open Date:    | Close of business May 31, 2023                   |
| For:                | Issuance and Cancellation                        |
| Reason:             | OTHER  |
| THE BOOKS WILL BE C | LOSED FOR ISSUANCES AND CANCELLATIONS FROM THE   |
| CLOSE OF BUSINESS M | MAY 23, 2023 THROUGH THE CLOSE OF BUSINESS       |
|                     | ECTION WITH THE UPCOMING ANNUAL                  |
|                     |  |

GENERAL MEETING TO BE HELD ON JUNE 9, 2023.

#### **Depositary Receipt Services**

#### **Contact Capital Markets Solutions**

| New York                | New York              | London                 |
|-------------------------|-----------------------|------------------------|
| Michael O'Leary         | Jason Zoppel          | Michael Woods          |
| michael.oleary@citi.com | jason.zoppel@citi.com | michael.woods@citi.com |

Group Email citiadr@citi.com

### Bloomberg: ADRC <GO>

For further information about Citi's Depositary Receipt Services, visit <u>www.citi.com/dr</u>.

© 2025 Citibank, N.A. All rights reserved. Citi and Arc Design and Citibank are trademarks and service marks of Citigroup Inc. or its affiliates, used and registered throughout the world. The above information is being provided solely for information purposes by Citi. At the time of publication, this information was believed to be accurate, but Citi makes no representation or warranty as to correctness of the information set forth above. The above information does not constitute a recommendation, solicitation or offer by Citi for the purchase or sale of any securities, nor shall this material be construed in any way as investment or legal advice or a recommendation, reference or endorsement by Citi.